source
- J&J’s Erleada reduces metastasis or death risk by 20% in early‑stage prostate cancer studyJohnson & Johnson presented data on its hormone therapy drug Erleada at the ASCO 2026 meeting. The study focused on men with early‑stage prostate cancer who received the drug around the time of sur…
- Oculis’ investigational eye drop OCS-01 fails Phase 3 trials for diabetic macular edema, shares tumbleOculis announced that its experimental eye drop OCS-01 did not meet primary endpoints in two Phase 3 studies aimed at treating diabetic macular edema. The trials were intended to evaluate the drug…